Stockscreener 앱 받기
3.51
1.68%
-0.06
시간 외 거래:
3.55
0.04
+1.14%
전일 마감가:
$3.57
열려 있는:
$3.58
하루 거래량:
550.61K
Relative Volume:
0.84
시가총액:
$222.80M
수익:
$56.91M
순이익/손실:
$-9.06M
주가수익비율:
29.25
EPS:
0.12
순현금흐름:
$-79.97M
1주 성능:
-20.05%
1개월 성능:
-12.47%
6개월 성능:
-19.59%
1년 성능:
-53.75%
1일 변동 폭
$3.50
$3.71
1주일 범위
$3.50
$4.39
52주 변동 폭
$2.9511
$21.88
Macrogenics Inc Stock (MGNX) Company Profile
명칭
Macrogenics Inc
전화
301-251-5172
주소
9704 MEDICAL CENTER DRIVE, Rockville, MD
MGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MGNX | 3.51 | 222.80M | 56.91M | -9.06M | -79.97M | 0.12 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-20 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-02-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-04 | 개시 | SMBC Nikko | Outperform |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-12 | 업그레이드 | Barclays | Underweight → Overweight |
| 2020-12-22 | 재개 | H.C. Wainwright | Buy |
| 2020-08-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-06-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2019-12-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-11-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Guggenheim | Neutral |
| 2019-02-07 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-02-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-02-06 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-12-10 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-05-31 | 개시 | Evercore ISI | Outperform |
| 2018-03-05 | 개시 | H.C. Wainwright | Buy |
| 2017-03-31 | 개시 | Raymond James | Outperform |
모두보기
Macrogenics Inc 주식(MGNX)의 최신 뉴스
MacroGenics' SWOT analysis: biotech stock faces pipeline hurdles amid cash strength - Investing.com India
MacroGenics downgraded to market perform by JMP, price target removed - MSN
FY2024 Earnings Estimate for MacroGenics Issued By B. Riley - MarketBeat
StockNews.com Upgrades MacroGenics (NASDAQ:MGNX) to Buy - MarketBeat
MacroGenics FY2024 EPS Estimate Increased by HC Wainwright - MarketBeat
Leerink Partnrs Increases Earnings Estimates for MacroGenics - MarketBeat
MacroGenics puts the brakes on vobra duo development - The Pharma Letter
MacroGenics downgraded to Market Perform from Outperform at JMP Securities - TipRanks
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights - Benzinga
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2024 Earnings Call Transcript - Insider Monkey
MacroGenics (NASDAQ:MGNX) Rating Lowered to "Market Perform" at JMP Securities - MarketBeat
MacroGenics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire
MacroGenics (MGNX) to Present at Guggenheim and Stifel Healthcare Conferences | MGNX Stock News - StockTitan
Earnings call: MacroGenics reports a revenue jump to $110.7 million By Investing.com - Investing.com South Africa
Earnings call: MacroGenics reports a revenue jump to $110.7 million - Investing.com India
MacroGenics Margenza rights sale a positive, says Leerink - TipRanks
MacroGenics (NASDAQ:MGNX) Receives Neutral Rating from HC Wainwright - MarketBeat
MacroGenics Inc earnings beat by $0.69, revenue topped estimates - Investing.com Australia
Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments - GuruFocus.com
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - GlobeNewswire
MacroGenics Inc. Reports Strong Revenue Growth - TipRanks
MacroGenics: Q3 Earnings Snapshot - Barchart
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript - Nasdaq
Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings - Yahoo Finance
MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
MacroGenics Q3 2024 Earnings Preview - MSN
Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Effective February 28, 2025 - Marketscreener.com
Q3 2024 MacroGenics Inc Earnings Call Transcript - GuruFocus.com
Macrogenics Earnings Preview - Benzinga
Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result - GuruFocus.com
MacroGenics (NASDAQ:MGNX) Lowered to Sell Rating by StockNews.com - MarketBeat
Masashi Miyamoto to become chairman and CEO of Kyowa Kirin - BioCentury
MacroGenics CEO Scott Koenig to resign early next year - Investing.com India
MacroGenics Announces Leadership Transition - GlobeNewswire
MacroGenics (MGNX) Scheduled to Post Earnings on Tuesday - MarketBeat
MacroGenics Co-Founder Koenig Stepping Down as President, CEO - MarketWatch
MacroGenics CEO Scott Koenig to resign early next year By Investing.com - Investing.com UK
Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year - Marketscreener.com
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - GlobeNewswire
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Macrogenics Inc (MGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):